Denali therapeutics and biogen announce initiation of phase 2b study of lrrk2 inhibitor in parkinson's disease

South san francisco, calif. and cambridge, mass., may 31, 2022 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli), and biogen inc. (nasdaq:biib) today announced that dosing has commenced in the global phase 2b luma study to evaluate the efficacy and safety of biib122 (dnl151), as compared to placebo in approximately 640 participants with early-stage parkinson's disease.
DNLI Ratings Summary
DNLI Quant Ranking